KalVista Pharmaceuticals, Inc.
DE ˙ DB ˙ US4834971032
23,01 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionRhumbline Advisers
Latest Disclosed Ownership47,469 shares
Latest Disclosed Value $ 955,539
Rhumbline Advisers reports 0.16% increase in ownership of 4XC1 / KalVista Pharmaceuticals, Inc.

On May 12, 2026 - Rhumbline Advisers filed a 13F-HR form disclosing ownership of 47,469 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1) valued at $735,770 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 47,391 shares of KalVista Pharmaceuticals, Inc.. This represents a change in shares of 0.16% during the quarter. The current value of the position is $1,092,262 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Kalvista Pharmaceutical COM 483497103 47,469 78 0.16 956 24.84 0.0008
2026-02-13 2025-12-31 13F Kalvista Pharmaceutical COM 483497103 47,391 -5,407 -10.24 765 18.97 0.0006
2025-11-06 2025-09-30 13F Kalvista Pharmaceutical COM 483497103 52,798 -1,578 -2.90 643 4.72 0.0005
2025-08-12 2025-06-30 13F Kalvista Pharmaceutical COM 483497103 54,376 1,458 2.76 615 0.66 0.0005
2025-05-29 2025-03-31 13F/A-1 Kalvista Pharmaceutical COM 483497103 52,918 1,762 3.44 611 40.88 0.0006
2025-04-08 2025-03-31 13F Kalvista Pharmaceutical COM 483497103 52,918 1,762 611 0.0006
2025-05-29 2024-12-31 13F/A-1 Kalvista Pharmaceutical COM 483497103 51,156 877 1.74 433 -25.60 0.0004
2025-01-30 2024-12-31 13F Kalvista Pharmaceutical COM 483497103 51,156 877 433 0.0004
2024-11-12 2024-09-30 13F Kalvista Pharmaceutical COM 483497103 50,279 -2,949 -5.54 582 -7.18 0.0005
2024-08-01 2024-06-30 13F Kalvista Pharmaceutical COM 483497103 53,228 5,908 12.49 627 11.76 0.0006
2024-05-09 2024-03-31 13F Kalvista Pharmaceutical COM 483497103 47,320 1,959 4.32 561 1.08 0.0005
2024-02-08 2023-12-31 13F Kalvista Pharmaceutical COM 483497103 45,361 3,466 8.27 556 37.72 0.0006
2023-11-09 2023-09-30 13F Kalvista Pharmaceutical COM 483497103 41,895 164 0.39 403 7.47 0.0005
2023-08-08 2023-06-30 13F Kalvista Pharmaceutical COM 483497103 41,731 2,909 7.49 376 0.0004
2023-05-11 2023-03-31 13F Kalvista Pharmaceutical COM 483497103 38,822 1,237 3.29 0 -100.00 0.0004
2023-02-14 2022-12-31 13F Kalvista Pharmaceutical COM 483497103 37,585 72 0.19 254 -53.31 0.0003
2022-11-10 2022-09-30 13F Kalvista Pharmaceutical COM 483497103 37,513 2,844 8.20 544 59.53 0.0008
2022-08-11 2022-06-30 13F Kalvista Pharmaceutical COM 483497103 34,669 12,519 56.52 341 4.60 0.0005
2022-05-12 2022-03-31 13F Kalvista Pharmaceutical COM 483497103 22,150 3,100 16.27 326 29.37 0.0004
2022-02-10 2021-12-31 13F Kalvista Pharmaceutical COM 483497103 19,050 -11 -0.06 252 -24.32 0.0003
2021-11-12 2021-09-30 13F Kalvista Pharmaceutical COM 483497103 19,061 897 4.94 333 -23.45 0.0005
2021-08-05 2021-06-30 13F Kalvista Pharmaceutical COM 483497103 18,164 -5,013 -21.63 435 -26.89 0.0006
2021-05-06 2021-03-31 13F Kalvista Pharmaceutical COM 483497103 23,177 4,188 22.05 595 64.82 0.0008
2021-02-10 2020-12-31 13F Kalvista Pharmaceutical COM 483497103 18,989 3,236 20.54 361 82.32 0.0005
2020-11-12 2020-09-30 13F Kalvista Pharmaceutical COM 483497103 15,753 -1,897 -10.75 198 -7.48 0.0003
2020-08-13 2020-06-30 13F Kalvista Pharmaceutical COM 483497103 17,650 6,923 64.54 214 160.98 0.0004
2020-05-06 2020-03-31 13F Kalvista Pharmaceutical COM 483497103 10,727 -150 -1.38 82 -57.73 0.0002
2020-02-05 2019-12-31 13F Kalvista Pharmaceutical COM 483497103 10,877 238 2.24 194 57.72 0.0003
2019-10-23 2019-09-30 13F Kalvista Pharmaceutical COM 483497103 10,639 -80 -0.75 123 -48.10 0.0002
2019-08-14 2019-06-30 13F Kalvista Pharmaceutical COM 483497103 10,719 10,719 237 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.